Shares of Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) saw strong trading volume on Monday . 203,802 shares changed hands during trading, an increase of 33% from the previous session’s volume of 153,223 shares.The stock last traded at $10.25 and had previously closed at $9.55.

A number of equities analysts have recently weighed in on the stock. Canaccord Genuity reissued a “buy” rating and set a $22.00 price target on shares of Aquinox Pharmaceuticals in a research report on Wednesday, August 17th. Zacks Investment Research cut shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 9th. Needham & Company LLC initiated coverage on shares of Aquinox Pharmaceuticals in a research report on Thursday, May 12th. They issued a “buy” rating and a $25.00 price objective on the stock. Finally, Jefferies Group boosted their price objective on shares of Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the company a “hold” rating in a research report on Friday, August 5th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. Aquinox Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $19.86.

The firm’s market cap is $177.97 million. The stock’s 50 day moving average is $8.62 and its 200 day moving average is $8.37.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by $0.22. Equities research analysts anticipate that Aquinox Pharmaceuticals Inc. will post ($2.08) earnings per share for the current fiscal year.

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.